期刊文献+

优化阿司匹林使用 平衡获益和风险

Optimization of the use of aspirin: Balance between benefits and risks
原文传递
导出
摘要 阿司匹林可显著降低心血管事件,而在一级预防中需评估获益风险,中危到高危患者在评估出血风险后应该给予阿司匹林,肿瘤获益可能增加了一级预防的净获益。阿司匹林引起的颅内出血和消化道出血呈剂量依赖性,但总体致命性出血无显著增加,出血的防治应该以预防为主,对于消化道损伤高危人群应该给予筛查并预防性使用胃肠道黏膜保护药物。 Aspirin can significantly reduce the cardiovascular events. For the primary prevention, most of the evidence suggested that medium- to high-risk patients should be given low-dose aspirin after the risk of bleeding is assessed. The prevention of cancer may increase the net clinical benefit regarding the total mortality. The intracranial hemorrhage and gastrointestinal bleeding associated with aspirin are dose-dependently increased, but fatal bleeding is not significantly increased as compared with placebo. For the prevention of gastrointestinal injury, high-risk patients should be screened for Helicobaetor pylori and considered undergoing prophylactic treatment with proton pump inhibitor.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2015年第1期24-26,共3页 Chinese Journal of Practical Internal Medicine
关键词 阿司匹林 心血管事件 aspirin cardiovascular events
  • 相关文献

参考文献15

  • 1Antithrombotic Trialists'(AqT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials[J]. Lancet, 2009, 373: 1849-1860.
  • 2Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice(version 2012). "[he Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) [J]. Eur Heart.], 2012, 33: 1635-1701.
  • 3Vandvik PO, Lincoff AM, Gore JM, et at. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy andPrevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical PracticeGuidelines[J]. Chest, 2012, 141: e637S-638S.
  • 4中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心血管病预防指南[J].中华心血管病杂志,2011,39:3-22.
  • 5Halvorsen S, Andreotti F, ten Berg JM, et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis[J]. J Am Coil Cardiol, 2014, 64(3): 319-27.
  • 6中华医学会糖尿病学分会.中国2型糖尿病防治指南/2010年版[M].北京:北京大学医学出版社,2011:5.
  • 7Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation[J]. Circulation, 2010, 121: 2694-2701.
  • 8Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortalit)5 and non-vascular death: analysis of the time course of risks and benefits in Sl randomised controlled trials[J]. Lancet, 2012, 379(9826): 1602-1612.
  • 9Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients[J]. BMJ, 2002, 324: 71-86.
  • 10McQ_uaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials[J], AmJ Med, 2006, 119(8): 624-638.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部